Characterization of potent and broadly neutralizing monoclonal antibodies against sars-cov-2, its variants, and related coronaviruses and methods of use
US-2024343781-A1 · Oct 17, 2024 · US
Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2] · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C07K16/104 |
| Official title | Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2] |
| Display label | Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2] |
| Total patents | 426 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is rapidly growing.
| Year | Patents |
|---|---|
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 6 |
| 2021 | 30 |
| 2022 | 39 |
| 2023 | 121 |
| 2024 | 121 |
| 2025 | 86 |
| 2026 | 14 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Multivalent anti-SARS-CoV-2 nanobodies
US-12098186-B1 · Sep 24, 2024 · US
Methods for Monoclonal Antibody Generation
US-2024228595-A1 · Jul 11, 2024 · US
Virus-like particles and uses thereof
US-11453886-B2 · Sep 27, 2022 · US
Multimeric sars-cov-2 binding molecules and uses thereof
US-2022267415-A1 · Aug 25, 2022 · US
Amino Acid Sequence Derived from Sars-Cov-2 and Use Thereof
US-2022242916-A1 · Aug 4, 2022 · US
Compositions and methods for treating a covid-19 infection
US-2022235119-A1 · Jul 28, 2022 · US
S309 chimeric antigen receptors and methods of use
US-2022184125-A1 · Jun 16, 2022 · US
Method for detection of viral infections using split enzymes
US-2022178923-A1 · Jun 9, 2022 · US
Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US-11345741-B2 · May 31, 2022 · US
Single Domain Antibodies to SARS-CoV-2 Nucleocapsid Protein
US-2022135654-A1 · May 5, 2022 · US
Compositions for preventing or treating viral and other microbial infections
US-2022119501-A1 · Apr 21, 2022 · US
Anti-RSV monoclonal antibody formulation
US-11286294-B2 · Mar 29, 2022 · US
Cr3022 chimeric antigen receptors and methods of use
US-2022048978-A1 · Feb 17, 2022 · US
ANTI-SARS-CoV-2 MONOCLONAL ANTIBODIES
US-2022017604-A1 · Jan 20, 2022 · US
Variant nucleic acid libraries for coronavirus
US-2021395344-A1 · Dec 23, 2021 · US
Methods for Treating or Preventing SARS-CoV-2 Infections and COVID-19 with Anti-SARS-CoV-2 Spike Glycoprotein Antibodies
US-2021395345-A1 · Dec 23, 2021 · US
Stereotypic neutralizing vh clonotypes against sars-cov-2 rbd in covid-19 patients and the healthy population
US-2021395346-A1 · Dec 23, 2021 · US
Compositions and methods for preventing and treating coronavirus infection - sars-cov-2 vaccines
US-2021388032-A1 · Dec 16, 2021 · US
Antibodies to sars-coronavirus (covid-19) s1 spike protein
US-2021388065-A1 · Dec 16, 2021 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C07K16/104?
- CPC C07K16/104 is the Cooperative Patent Classification code for “Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2].”
- How many patents are filed under CPC C07K16/104 (Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2])?
- Our database includes 426 publications tagged with this CPC code.
- Is patent activity under CPC C07K16/104 growing?
- Publication counts under this code: 121 in 2024 vs 86 in 2025 (latest complete years).